Accessing Amivantamab in China — Eligibility Explained
Amivantamab, marketed as intravenous RYBREVANT, is a bispecific antibody directed at EGFR and MET. In non-small cell lung cancer, the exact EGFR mutation and previous treatment help determine which labelled regimen is relevant.
EGFR exon 20 insertion disease
The FDA’s March 2024 notice covers amivantamab with carboplatin and pemetrexed as first-line treatment for locally advanced or metastatic NSCLC with an EGFR exon 20 insertion. It also covers single-agent treatment after progression on or after platinum chemotherapy.
Sources: FDA · 2024-03-01
EGFR exon 19 deletion or L858R
The FDA approved amivantamab with lazertinib in August 2024 as first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. The molecular test result and treatment history are therefore central to the oncology review.
Sources: FDA · 2024-08-19
Risks discussed with the oncology team
The US prescribing information includes infusion reactions, interstitial lung disease/pneumonitis, skin and eye toxicity, and fetal harm. Venous blood clots are a particular concern with the lazertinib combination. Monitoring and preventive measures depend on the prescribed regimen.
A hospital enquiry in China
Send the pathology report, molecular test, recent imaging and treatment history to the treating team. Ask which formulation and regimen it proposes, the local supply and approval pathway, required monitoring and an itemised quotation. A US indication does not by itself confirm hospital stock or the applicable Chinese pathway.
Frequently asked questions
Is amivantamab suitable for every lung cancer?
What information is needed for a quotation?
This article was produced with AI assistance and reviewed against Uwell Cloud editorial and compliance standards.